Evaxion Biotech: Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

EVX-01 induced positive clinically relevant immune responses in all assessed patientsBooster immunizations tended to increase the immune responseThe observed immune responses were mediated by both CD4+

Related Keywords

Chicago ,Illinois ,United States ,Copenhagen ,Køavn ,Denmark ,Australia ,Ukraine ,Italy ,Russia ,Mccormick Place ,American ,Lausen Nielsen ,Christian Kanstrup ,Exchange Commission ,Securities Exchange ,American Society Of Clinical Oncology ,Merck Sharp Dohme ,American Society ,Clinical Oncology ,Annual Meeting ,Merck Sharp ,Securities Act ,Securities Exchange Act ,Middle East ,Annual Report ,Ihr Portfolio ,